Posted by Michael Wonder on 27 Apr 2024
Highlights from the 22-25 April 2024 CHMP meeting
26 April 2024 - The EMA’s CHMP recommended eight medicines for approval at its April 2024 meeting.
The CHMP recommended granting a marketing authorisation for Altuvoct (efanesoctocog alfa), for the treatment and prophylaxis of bleeding in patients with haemophilia A, a rare inherited bleeding disorder caused by lack of factor VIII.
